Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: Emerging links

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 5, 2007, Pages 524-533

  Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Angiogenesis; Anti factor IIa; Anti factor Xa; Glycosaminoglycans; Heparin; Inflamation; Low molecular weight heparin; Thrombosis; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; REVIPARIN; TINZAPARIN; WARFARIN;

ANGIOGENESIS; ANTICOAGULANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CANCER PATIENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; ENDOTHELIAL DYSFUNCTION; ENTERITIS; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; LUNG EMBOLISM; MONOTHERAPY; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; THROMBOEMBOLISM; THROMBOSIS; TREATMENT DURATION; ULCERATIVE COLITIS;

ANIMALS; ANTICOAGULANTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFLAMMATION; NEOVASCULARIZATION, PATHOLOGIC; THROMBOSIS;

EID: 34547094356     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-982084     Document Type: Conference Paper

References (97)

1. Weitz JI. Low-molecular-weight heparin. N Engl J Med 1997;337:688-698
2. Aguilar D, Goldhaber SZ. Clinical uses of low molecular weight heparin. Chest 1999;115:1418-1423
3. Mousa SA, Fareed J. Overview: from heparin to low molecular weight heparin: beyond anticoagulation. Curr Opin Investig Drugs 2001;2(8):1077-1080
4. Mousa SA. Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: implications for management of vascular disorders. Semin Thromb Hemost 2000;26(suppl 1):39-46
5. Taheri SA, Lazar L, Haddad G, Castaldo R, Wilson M, Mousa S. Diagnosis of deep venous thrombosis by use of soluble necrosis factor receptor. Angiology 1998;49:537-541
6. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993;82: 3253-3258
7. Lantz M, Thysell H, Nilsson E, Olsson I. On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest 1991;88:2026-2031
8. Tyrell DJ, Kilfeather S, Page CP. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci 1995;16:198-204
9. Hocking D, Ferro TJ, Johnson A. Dextran sulfate and heparin sulfate inhibit platelet-activating factor-induced pulmonary edema. J Appl Physiol 1992;72:179-185
10. Darien BJ, Fareed J, Centgraf KS, et al. Low molecular weight heparin prevents the pulmonary hemodynamic and pathomorphologic effects of endotoxin in a porcine acute lung injury model. Shock 1998;9:274-281
11. Meyer J, Cox CS, Herndon DN, et al. Heparin in experimental hyperdynamic sepsis. Crit Care Med 1993;21:84-89
12. Hiebert LM, Liu JM. Heparin protects cultured arterial endothelial cells from damage by toxic oxygen metabolites. Atherosclerosis 1990;83:47-51
13. Matzner Y, Marx G, Drexler R, Eldor A. The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb Haemost 1984;52:134-137
14. Bazzoni G, Beltran Nunez A, Mascellani G, Bianchini P, Dejana E, Del Maschio A. Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte functions. J Lab Clin Med 1993;121:268-275
15. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:401S-428S
16. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-3083
17. Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000;84:805-810
18. Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488
19. Lee AY, Levine MN, Baker RI, et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153
20. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Intern Med 2002;162:1729-1735
21. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-662
22. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;337:663-669
23. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 2004;140:175-183
24. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386-1389
25. Grifoni S, Olivotto I, Cecchini P, et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000;101:2817-2822
26. Agnelli G, Becattini C, Kirschstein T. Thrombolysis vs heparin in the treatment of pulmonary embolism. Arch Intern Med 2002;162:2537-2541
27. Thabut G, Thabut D, Myers RP, et al. Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am Coll Cardiol 2002;40:1660-1667
28. Konstantinides S, Gebel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002;347:1143-1150
29. Ten Wolde M, Sohne M, Quak E, Mac Gillavry MR, Buller HR. Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med 2004;164:1685-1689
30. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7
31. Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997;82:423-428
32. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769-774
33. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ III. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761-768
34. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661-1665
35. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-907
36. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001;345:165-169
37. Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001;103:2453-2460
38. Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003;139:19-25
39. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-398
40. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-1434
41. Kearon C, Ginsberg JS, Anderson DR, et al. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost 2004;2:743-749
42. Vancheri C, Mastruzzo C, Armato F, et al. Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis. J Allergy Clin Immunol 2001;108:703-708
43. Diamant Z, Timmers MC, van der Veen H, Page CP, van der Meer FJ, Sterk PJ. Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Am J Respir Crit Care Med 1996;153:1790-1795
44. Garrigo J, Danta I, Ahmed T. Time course of the protective effect of inhaled heparin on exercise-induced asthma. Am J Respir Crit Care Med 1996;153:1702-1707
45. Gaffney A, Gaffney P. Rheumatoid arthritis and heparin. Br J Rheumatol 1996;35:808-809
46. Bowler SD, Smith SM, Lavercombe PS. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis 1993;147:160-163
47. Dwarakanath AD, Yu LG, Brookes C, Pryce D, Rhodes JM. Sticky neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut 1995;37:585-588
48. Petitou M, Herault J-P, Bernat A, et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 1999;398:417-422
49. Tyrrel DJ, Horne AP, Holme KR, Preuss JMH, Page CP. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999;46:151-208
50. Salas A, Sans M, Soriano A, et al. Heparin attenuates TNF-induced inflammatory response through a CD11b dependent mechanism. Gut 2000;47:88-96
51. Panés J, Perry M, Granger DN. Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. Br J Pharmacol 1999;126:537-550
52. Lever R, Hoult JRS, Page CP. The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leukocytes to vascular endothelium in vitro. Br J Pharmacol 2000;129:533-540
53. Gaffney PR, Doyle CT, Gaffney A, Hogan J, Hayes DP, Annis P. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 1995;90:220-223
54. Gaffney P, Gaffney A. Heparin therapy in refractory ulcerative colitis - an update. Gastroenterology 1996;110:A913 (abst)
55. Evans RC, Rhodes JM. Treatment of corticosteroid-resistant ulcerative colitis with heparin. A report of nine cases. Gut 1995;37:A49 (abst)
56. Brazier F, Yzet T, Duchmann JC, et al. Effect of heparin treatment on extra intestinal manifestations associated with inflammatory bowel diseases. Gastroenterology 1996;110:A872 (abst)
57. Brazier F, Yzet T, Boruchowicz A, et al. Treatment of ulcerative colitis with heparin. Gastroenterology 1996;110:A872 (abst)
58. Dupas JL, Brazier F, Yzet T, et al. Treatment of active Crohn's disease with heparin. Gastroenterology 1996;110:A900 (abst)
59. Folwaczny C, Spannagl M, Wiebecke W, et al. Heparin in the treatment of highly active inflammatory bowel disease (IBD). Gastroenterology 1996;110:A908 (abst)
60. Dwarakanath AD, Yu LG, Brookes C, Pryce D, Rhodes JM. "Sticky" neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut 1995;37:585-588
61. Teixeira MM, Hellewell PG. Suppression by intradermal administration of heparin of eosinophil accumulation but not edema formation in inflammatory reactions in guinea-pig skin. Br J Pharmacol 1993;110:1496-1500
62. Carr J. The anti-inflammatory action of heparin: heparin as an antagonist to histamine, bradykinin and prostaglandin E1. Thromb Res 1979;16:507-516
63. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins: implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998;101:877-889
64. Diamond MS, Alon R, Parkos CA, Quinn MT, Springer TA. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD18). J Cell Biol 1995;130:1473-1482
65. Benimetskaya L, Loike JD, Khaled Z, et al. Mac-1 (CD11b/CD18) is an oligodeoxy-nucleotide-binding protein. Nat Med 1997;3:414-420
66. Emanuele RM, Fareed J. The effect of molecular weight on the bioavailability of heparin. Thromb Res 1987;48:591-596
67. Brieger D, Dawes J. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb Haemost 1997;77:317-322
68. Mousa SA, Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 2004;92:627-633
69. Mousa SA, Kaiser B. Tissue factor pathway inhibitor in thrombosis and beyond: role of heparin. Drugs Future 2004;29:751-766
70. Boneu B, Caranobe C, Cadroy Y, et al. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit. Semin Thromb Hemost 1988;14:18-27
71. Sutor AH, Massicotte P, Leaker M, Andrew M. Heparin therapy in pediatric patients. Semin Thromb Hemost 1997;23:303-319
72. Majerus P, Broze JG, Miletich J. Anticoagulant, thrombolytic and antiplatelet drugs. In: Hardman J, Limbird L, Molinoff P, Ruddon R, Goodman A, eds. Goodman & Gilman's, The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996:1341-1359
73. Silverstein R. Drugs affecting hemostosis. In: Munson P, Mueller R, Breeze G, eds. Munson's Principles of Pharmacology. New York: Chapman & Hall; 1995:1123-1143
74. Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993;88:2045-2048
75. Itoh K, Nakao A, Kishimoto W, Takagi H. Heparin effects on superoxide production by neutrophils. Eur Surg Res 1995;27:184-188
76. Attanasio M, Gori AM, Giusti B, et al. Cytokine gene expression in human LPS- and IFNgamma-stimulated mononuclear cells is inhibited by heparin. Thromb Haemost 1998;79:959-962
77. Dandona P, Qutob T, Hamouda W, Bakri F, Aljada A, Kumbkarni Y. Heparin inhibits reactive oxygen species generation by polymorphonuclear and mononuclear leucocytes. Thromb Res 1999;96:437-443
78. Friedrichs GS, Kilgore KS, Manley PJ, Gralinski MR, Lucchesi BR. Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart. Circ Res 1994;75:701-710
79. Black SC, Gralinski MR, Friedrichs GS, Kilgore KS, Driscoll EM, Lucchesi BR. Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc Res 1995;29:629-636
80. Lucchesi BR, Kilgore KS. Complement inhibitors in myocardial ischemia/reperfusion injury. Immunopharmacology 1997;38:27-42
81. Hawari FI, Shykoff BE, Izzo JL Jr. Heparin attenuates norepinephrine-induced venoconstriction. Vasc Med 1998;3:95-100
82. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and pro-inflammatory cytokines. J Clin Invest 1995;96:60-68
83. Merwin RM, Algire GH. Induction of plasma-cell neoplasms and fibrosarcomas in BALB/c mice carrying diffusion chambers. Proc Soc Exp Biol Med 1959;101(3):437-439
84. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000;21:505-515
85. Folkman J. Proceedings: tumor angiogenesis factor. Cancer Res 1974;34(8):2109-2113
86. Folkman J, Langer R, Linhardt R, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983;221:719-725
87. Folkman J, Shing Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 1992;313:355-364
88. Mousa SA, Mohamed S. Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anticancer efficacy. Oncol Rep 2004;12:683-688
89. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous LMWH compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-982
90. Simonneau G, Sors H, Charbonnier B, et al. A comparison of LMWH with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;337:663-669
91. Dahlback B. Blood coagulation. Lancet 2000;355:1627-1632
92. Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997;78:471-477
93. Von Tempelhoff G-F, Hareberg J, Niemann F, Hommel G, Kirkpatrik CJ, Heilmann L. Subcutaneous heparin treatment increases survival in small cell lung cancer. Int J Oncol 2000;16:815-824
94. Kakkar AK, Williamson RC. Antithrombotic therapy in cancer. BMJ 1999;318(7198):1571-1572
95. Kohanna FH, Sweeny J, Hussey S, Zacharski L, Salzman EW. Effect of perioperative low-dose heparin on the course of colon cancer. Surgery 1983;93:433-438
96. Leonard WJ, Lin JX. Cytokine receptor signaling pathways. J Allergy Clin Immunol 2000;105:877-888
97. Mousa S A, Linhardt R, Francis JL, Amirkhosravi A. Antimetastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost 2006;96:816-821